Trial Profile
A phase I randomized, single blind, controlled, single center study to evaluate the safety and immunogenicity of a dose range of glycoconjugate antigen vaccine of group B streptococcus [streptococcal B vaccine conjugate] in healthy women 18- 40 years of age.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2011
Price :
$35
*
At a glance
- Drugs Streptococcal B vaccine conjugate (Primary)
- Indications Streptococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 07 Dec 2011 Actual end date for extension trial (NCT01053767) is December 2010.
- 07 Dec 2011 Actual end date for extension trial (NCT01053767) is December 2010.
- 07 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov record (Extension trial: NCT01053767)